Chronic Hepatitis B VirusMarket Size, Epidemiology, Leading Companies, Drugs and Competitive Analysis by DelveInsight

(Albany, US) DelveInsight has launched a new report on "Chronic Hepatitis B Virus - Market Insights, Epidemiology, and Market Forecast-2030".

DelveInsight's "Chronic Hepatitis B Virus - Market Insights, Epidemiology, and Market Forecast-2030" report delivers an in-depth understanding of the Chronic Hepatitis B Virus , historical and forecasted epidemiology as well as the Chronic Hepatitis B Virus market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Reports key facts

1.       In 2016, WHO set the target of eliminating chronic HBV as a public health threat by 2030. Elimination of HBV by 2030 will require diagnosis of 90% of people infected with HBV and antiviral treatment of 80% of diagnosed people eligible for therapy.

2.       As per DelveInsight’s analysts, the t otal prevalent cases of CHB were 5,797,240 in 2017, which are expected to rise during the study period (2017-2030).

3.       Among the 7MM, the United States accounted for nearly 39% of the total prevalent population of CHB in the year 2017.

4.       Low diagnosis rate observed across the 7MM and possible factors could be people infected with CHB often have no symptoms and not aware about CHB and also there is overall lack of awareness surrounding HBV necessitates provider education on cut-off values for abnormal levels of alanine aminotransferase (ALT)

Request for Sample Page:

View Report:

Scope of Report:

·         The report covers the descriptive overview of Chronic Hepatitis B Virus , explaining its causes, signs and symptoms, pathophysiology, diagnosis and currently available therapies

·         Comprehensive insight has been provided into the Chronic Hepatitis B Virus epidemiology and treatment in the 7MM

·         Additionally, an all-inclusive account of both the current and emerging therapies for Chronic Hepatitis B Virus are provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape

·         A detailed review of Chronic Hepatitis B Virus market; historical and forecasted is included in the report, covering drug outreach in the 7MM

·         The report provides an edge while developing business strategies, by understanding trends shaping and driving the global Chronic Hepatitis B Virus market

Chronic Hepatitis B Virus is a life-threatening and one of the most common liver infections around the globe. It is caused by the hepatitis B virus (HBV), which attacks and injures the liver. HBV can cause both acute and chronic disease. If an individual suffers from HBV infection which lasts more than six months, then the infection becomes chronic. Having chronic hepatitis B (CHB) increases the risk of developing liver failure, liver cancer or cirrhosis. HBV is mostly transmitted through blood and infected bodily fluids. It can be passed to others through direct contact with blood, unprotected sex, use of illegal drugs, unsterilized or contaminated needles.

Request for Sample Page:

View Report:


The Chronic Hepatitis B Virusepidemiology division provides insights about historical and current patient pool and forecasted trend for every seven major countries. The Chronic Hepatitis B Virus epidemiology data are studied through all possible division to give a better understanding of the Disease scenario in 7MM. The Chronic Hepatitis B Virus epidemiology segment covers the epidemiology data in the US, EU5 countries (Germany, Spain, Italy, France, and the UK), and Japan from 2017 to 2030. It also helps to recognize the causes of current and forecasted trends by exploring numerous studies, survey reports and views of key opinion leaders.

Some of key companies 

·         GlaxoSmithKline

·         Ionis Pharma

·         Janssen Sciences

·         Hoffmann-La Roche

·         Gilead Sciences

·         Assembly Biosciences

Name of drugs covered 

·         GSK3228836

·         JNJ-56136379 And JNJ-3989 ± JNJ-6379 +NUC

·         RG7907 + RG7854 + NUC

·         Selgantolimod (GS-9688)

·         Vebicorvir (ABI-H0731) +NUC

·         And Many Others

View Report:

Request for Sample Page:

Table of content:

1. Key Insights

2. Executive Summary of Chronic Hepatitis B Virus

3. Competitive Intelligence Analysis for Chronic Hepatitis B Virus

4. Chronic Hepatitis B Virus : Market Overview at a Glance

5. Chronic Hepatitis B Virus : Disease Background and Overview

6. Patient Journey

7. Chronic Hepatitis B Virus Epidemiology and Patient Population

8. Treatment Algorithm, Current Treatment, and Medical Practices

9. Unmet Needs

10. Key Endpoints of Chronic Hepatitis B Virus Treatment

11. Marketed Products

List to be continued in report

12. Emerging Therapies

List to be continued in report

13. Chronic Hepatitis B Virus: Seven Major Market Analysis

14. Attribute analysis

15. 7MM: Market Outlook

16. Access and Reimbursement Overview of Chronic Hepatitis B Virus

17. KOL Views

18. Market Drivers

19. Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

23. About DelveInsight

Request for Sample Page:

View Report:

Media Contact Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Phone: +19193216187
City: Albany
State: New York
Country: United States Website: